{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=5",
    "query": {
      "intervention": "dose level 1",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 29075,
    "total_pages": 2908,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T05:12:52.006Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06100913",
      "title": "Immunology of Ebola Vaccine",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ebola Virus Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Deuterium Labeled Water",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-08-06",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 2,
      "location_summary": "Decatur, Georgia • St Louis, Missouri",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06100913"
    },
    {
      "nct_id": "NCT01872260",
      "title": "Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "BYL719",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 259,
      "start_date": "2013-10-22",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 10,
      "location_summary": "San Diego, California • San Francisco, California • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01872260"
    },
    {
      "nct_id": "NCT05859724",
      "title": "Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "NM26-2198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Yellow Jersey Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2023-05-10",
      "completion_date": "2024-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 6,
      "location_summary": "Fountain Valley, California • Glendale, California • San Diego, California + 3 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05859724"
    },
    {
      "nct_id": "NCT02815059",
      "title": "Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-09-28",
      "completion_date": "2018-01-09",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02815059"
    },
    {
      "nct_id": "NCT06444880",
      "title": "Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SMARCB1-Deficient Malignancies",
        "Epithelioid Sarcoma",
        "Renal Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ubamatamab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-10-09",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06444880"
    },
    {
      "nct_id": "NCT02889562",
      "title": "Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Bypass Grafting",
        "Postoperative Atrial Fibrilation",
        "Stroke",
        "Systemic Embolism",
        "Deep Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanford Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2016-09",
      "completion_date": "2019-05-11",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889562"
    },
    {
      "nct_id": "NCT00744146",
      "title": "First Time in Human Study of Protexia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intervention for Nerve Agent Exposure"
      ],
      "interventions": [
        {
          "name": "Protexia",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PharmAthene, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 33,
      "start_date": "2008-09",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-09-17",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00744146"
    },
    {
      "nct_id": "NCT02230046",
      "title": "Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate (Treatment B)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 102,
      "start_date": "2014-10",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230046"
    },
    {
      "nct_id": "NCT01408888",
      "title": "A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY2189265",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2011-08",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2014-10-07",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408888"
    },
    {
      "nct_id": "NCT01195103",
      "title": "Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Procedural Sedation",
        "Regional Anesthesia Block",
        "Orthopedic Surgery"
      ],
      "interventions": [
        {
          "name": "Fospropofol disodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo + Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 13,
      "start_date": "2011-02",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-06-29",
      "last_synced_at": "2026-11-09T05:12:52.006Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01195103"
    }
  ]
}